Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AddLife ABSTU:1AD1 -3.52%88 EV-to-FCF is 18.32 as of Jul. 18, 2026, which is 28% below its 10-year median of 25.52. GuruFocus rates STU:1AD1 with a GF Score™ of 88/100 and a GF Value™ of €13.56. The stock has 5 warning signs investors should review. Among 414 Medical Devices & Instruments companies, AddLife AB ranks better than 61.59% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AddLife AB's Enterprise Value is €2,189.0 Mil.
AddLife AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €119.5 Mil. Therefore, AddLife AB's EV-to-FCF for today is 18.32.
The historical rank and industry rank for AddLife AB's EV-to-FCF or its related term are showing as below:
STU:1AD1'
s EV-to-FCF Range Over the Past 10 Years
Min: 14.63 Med: 25.52 Max: 50.53
Current: 18.66
During the past 13 years, the highest EV-to-FCF of AddLife AB was 50.53. The lowest was 14.63. And the median was 25.52.
STU:1AD1's EV-to-FCF is ranked better than 61.59% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.635
vs STU:1AD1: 18.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AddLife AB's share price for today is €14.54.
AddLife AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.449.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AddLife AB EV-to-FCF Related Terms
AddLife AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for AddLife AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, AddLife AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AddLife AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where AddLife AB's EV-to-FCF falls into.
AddLife AB's current Enterprise Value is €2,189.0 Mil.
AddLife AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €119.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AddLife AB (STU:1AD1) has a EV-to-FCF of 18.32 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on AddLife AB and its competitors. This is 28% below median its historical median of 25.52. Over the past decade, AddLife AB's EV-to-FCF has ranged from 14.63 to 50.53. According to the industry distribution chart, AddLife AB ranks #159 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 38.4%.
Is AddLife AB's EV-to-FCF too high?
AddLife AB's current EV-to-FCF of 18.32 is 28% below median its 10-year median of 25.52. Over the past 10 years, this metric has ranged from a low of 14.63 to a high of 50.53. The Medical Devices & Instruments industry median EV-to-FCF is 23.64. AddLife AB's value of 18.32 is 22.5% below this industry median. Based on the distribution chart, AddLife AB ranks #159 out of 414 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, AddLife AB has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AddLife AB ranks #159 out of 414 companies for EV-to-FCF. This puts AddLife AB in the upper half of its industry. The industry median EV-to-FCF is 23.64. AddLife AB's value of 18.32 is 22.5% below this benchmark. Historically, AddLife AB's own EV-to-FCF has ranged from 14.63 to 50.53 over the past decade. While the company's 10-year median is 25.52 vs. the industry median of 23.64, AddLife AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.64, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AddLife AB's current EV-to-FCF of 18.32 is 22.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on AddLife AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AddLife AB's current EV-to-FCF is 18.32, which is 28% below median its own 10-year median of 25.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
AddLife AB (STU:1AD1) has a current EV-to-FCF of 18.32. The stock's GF Value™ is €13.56, compared to a current price of €14.54 — trading 7.2% above its estimated fair value. The current EV-to-FCF is 18.32, which is 28% below median its 10-year median of 25.52 and 22.5% below the Medical Devices & Instruments industry median of 23.64. AddLife AB's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For AddLife AB (STU:1AD1), the current EV-to-FCF is 18.32 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AddLife AB (STU:1AD1) Overvalued in 2026?
Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued.
The current stock price of €14.54 is trading 7.2% above its estimated GF Value™ of €13.56.
Key valuation signals for STU:1AD1:
EV-to-FCF: 18.32 (28% below median its 10-year median of 25.52)
GF Value™: €13.56 vs. price of €14.54 (7.2% above fair value)
Industry Position: 22.5% below the Medical Devices & Instruments median (#159 of 414)
No single metric tells the full story. See the STU:1AD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
88GF Score
Get the complete analysis for STU:1AD1
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1AD1 has been successfully added to your 
